STAAR Surgical Company (STAA) Upgraded at BidaskClub
STAAR Surgical Company (NASDAQ:STAA) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Saturday.
A number of other research analysts also recently weighed in on STAA. Canaccord Genuity raised their target price on shares of STAAR Surgical from $9.00 to $11.00 and gave the company a “hold” rating in a research report on Thursday, August 3rd. TheStreet raised shares of STAAR Surgical from a “d+” rating to a “c” rating in a research report on Tuesday. Benchmark Co. raised their target price on shares of STAAR Surgical from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, August 14th. Finally, Zacks Investment Research raised shares of STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Three equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $12.00.
Shares of STAAR Surgical (STAA) traded up 1.29% during midday trading on Friday, reaching $11.75. 127,199 shares of the company were exchanged. The stock has a 50-day moving average price of $10.62 and a 200 day moving average price of $10.01. The company’s market capitalization is $483.02 million. STAAR Surgical has a 52-week low of $7.46 and a 52-week high of $12.35.
STAAR Surgical (NASDAQ:STAA) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.04. The business had revenue of $21.90 million during the quarter, compared to the consensus estimate of $22.15 million. STAAR Surgical had a negative net margin of 6.06% and a negative return on equity of 8.69%. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.02) earnings per share. Equities research analysts expect that STAAR Surgical will post ($0.11) EPS for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virtu KCG Holdings LLC acquired a new position in STAAR Surgical during the second quarter worth $118,000. Goldman Sachs Group Inc. acquired a new position in STAAR Surgical during the first quarter worth $111,000. Stephens Inc. AR increased its position in STAAR Surgical by 2.6% in the second quarter. Stephens Inc. AR now owns 12,238 shares of the medical instruments supplier’s stock worth $132,000 after buying an additional 315 shares during the period. Simplex Trading LLC increased its position in STAAR Surgical by 1,798.8% in the second quarter. Simplex Trading LLC now owns 12,779 shares of the medical instruments supplier’s stock worth $138,000 after buying an additional 12,106 shares during the period. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in STAAR Surgical during the second quarter worth $214,000. 75.79% of the stock is owned by institutional investors and hedge funds.
STAAR Surgical Company Profile
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with Analyst Ratings Network's FREE daily email newsletter.